{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:51:54Z","timestamp":1790319114016,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Pathologie"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.annpat.2020.02.023","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T17:07:23Z","timestamp":1585588043000},"page":"78-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Les cancers h\u00e9r\u00e9ditaires du sein vus par le pathologiste"],"prefix":"10.1016","volume":"40","author":[{"given":"Anne","family":"Vincent-Salomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bataillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5007-2964","authenticated-orcid":false,"given":"Lounes","family":"Djerroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annpat.2020.02.023_bib0110","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00439-013-1299-y","article-title":"The complex genetic landscape of familial breast cancer","volume":"132","author":"Melchor","year":"2013","journal-title":"Hum Genet"},{"key":"10.1016\/j.annpat.2020.02.023_bib0115","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.annpat.2020.02.023_bib0120","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/cc.10.8.15273","article-title":"Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations","volume":"10","author":"Dedes","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.annpat.2020.02.023_bib0125","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"72","author":"Easton","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2020.02.023_bib0130","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.7939630","article-title":"BRCA1 mutations in primary breast and ovarian carcinomas","volume":"266","author":"Futreal","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.annpat.2020.02.023_bib0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1155\/1999\/459486","article-title":"The pathology of hereditary breast cancer","volume":"15","author":"Lakhani","year":"1999","journal-title":"Dis Markers"},{"key":"10.1016\/j.annpat.2020.02.023_bib0140","doi-asserted-by":"crossref","first-page":"35616","DOI":"10.18632\/oncotarget.5348","article-title":"First description of a sporadic breast cancer in a woman with BRCA1 germline mutation","volume":"6","author":"Curtit","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.annpat.2020.02.023_bib0145","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdz132","article-title":"Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers","volume":"30","author":"Nones","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annpat.2020.02.023_bib0150","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","article-title":"Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype","volume":"11","author":"Lakhani","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2020.02.023_bib0155","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1054\/bjoc.2000.1438","article-title":"Low expression of bcl-2 in Brca1-associated breast cancers","volume":"83","author":"Freneaux","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annpat.2020.02.023_bib0160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-08-1560","article-title":"High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors","volume":"69","author":"Manie","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.annpat.2020.02.023_bib0165","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1038\/sj.onc.1209876","article-title":"Basal-like breast cancer and the BRCA1 phenotype","volume":"25","author":"Turner","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.annpat.2020.02.023_bib0170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10549-008-0087-1","article-title":"Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors","volume":"117","author":"Bane","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annpat.2020.02.023_bib0175","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/bcr2626","article-title":"Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations","volume":"12","author":"Banneau","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.annpat.2020.02.023_bib0180","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1038\/sj.onc.1208561","article-title":"Identification of molecular apocrine breast tumours by microarray analysis","volume":"24","author":"Farmer","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.annpat.2020.02.023_bib0185","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2020.02.023_bib0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-012-2375-z","article-title":"Prevalence of germline TP53 mutations in HER2+ breast cancer patients","volume":"139","author":"Rath","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annpat.2020.02.023_bib0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/PAP.0000000000000177","article-title":"Hereditary breast and ovarian cancer syndrome: moving beyond BRCA1 and BRCA2","volume":"25","author":"Hoang","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.annpat.2020.02.023_bib0200","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10549-018-5051-0","article-title":"Clinical implication of E-cadherin deficiency in lobular breast cancer","volume":"173","author":"Corso","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annpat.2020.02.023_bib0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10689-016-9869-5","article-title":"CDH1 germline mutations and hereditary lobular breast cancer","volume":"15","author":"Corso","year":"2016","journal-title":"Fam Cancer"},{"key":"10.1016\/j.annpat.2020.02.023_bib0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13058-018-0951-9","article-title":"Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers","volume":"20","author":"Renault","year":"2018","journal-title":"Breast Cancer Res"}],"container-title":["Annales de Pathologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649820300596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649820300596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:34:08Z","timestamp":1759332848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0242649820300596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0242649820300596"],"URL":"https:\/\/doi.org\/10.1016\/j.annpat.2020.02.023","relation":{},"ISSN":["0242-6498"],"issn-type":[{"value":"0242-6498","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les cancers h\u00e9r\u00e9ditaires du sein vus par le pathologiste","name":"articletitle","label":"Article Title"},{"value":"Annales de Pathologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annpat.2020.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}